安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Signatera – Circulating Tumor DNA Blood Test | Natera
Signatera™ is a highly sensitive and personalized MRD assay using ctDNA and is custom designed for each patient to help identify relapse earlier than standard of care tools
- What is Signatera? - Colontown University
Signatera is a new blood test that can identify molecular residual disease (MRD), or recurrent cancer, sooner than existing methods by detecting the presence of circulating tumor DNA (ctDNA) Signatera is a custom-designed test that is generated based on each patient’s unique set of tumor mutations
- Every Cancer Patient Needs to Know About the Signatera Test
Natera makes Signatera, a blood test that detects whether cancer has come back after treatment It works differently from any standard blood test or tumor marker your oncologist might order
- Signatera Test. Is it truly helpful and worthwhile?
"The Signatera™ Residual Disease Test is a custom-built blood test for people who have been diagnosed with breast cancer or other solid tumors Signatera™ can detect molecular residual disease (MRD) in the form of circulating tumor DNA—small fragments of DNA released by cancer cells "
- The Signatera Process
78753 | natera com SignateraTM has been developed and its performance characteristics determined by the CLIA-certified laborator performing the test The test has not been cleared or approved by the US Food and Drug Administration (FDA) CAP accredited, ISO 13485 certified, and CLIA certified © 2023 Natera, Inc
- Signatera (Sendout)
Test Information: Signatera™ is a mPCR-NGS assay for detection and quantification of circulating tumor DNA (ctDNA) in the plasma of patients previously diagnosed with cancer Individual-specific mutation signatures are identified by upfront tissue and matched normal whole exome sequencing
- Clinical performance of Signatera Genome assay in a cohort of patients . . .
Background: Circulating tumor DNA (ctDNA) has emerged as a powerful, minimally invasive biomarker of treatment response and pt prognosis Signatera, a tumor-informed, mPCR-NGS ctDNA assay, offers high sensitivity and specificity for detecting molecular residual disease (MRD)
- Signatera MRD Test Gets Breakthrough Device Designations
Signatera is a custom-built circulating tumor DNA (ctDNA) test for treatment monitoring and molecular residual disease (MRD) assessment in patients previously diagnosed with cancer
|
|
|